Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), which is a member of the human epidermal growth factor (HER)/ErbB family of receptor tyrosine kinases, wherein activation is known to induce survival and tumor growth of cancer cells [3]. The gene discussed is EGFR; the disease is cancer.